Prescribing reduced to just three prescriptions in the last week as new research highlights possible dangers
FRIDAY, May 29, 2020 (HealthDay News) — The VA health system has stopped nearly all use of hydroxychloroquine to treat COVID-19 patients, Veterans Affairs Secretary Robert Wilkie said at a House hearing on Thursday.
Wilkie said VA hospitals “ratcheted it down” to just three prescriptions in the last week as new research highlighted possible dangers and other possible treatments became available, the Associated Press reported. “I expect that trend to continue in the future,” Wilkie added. He defended the VA’s initial use of hydroxychloroquine to treat COVID-19 patients, saying there were few treatment options at the time.
The VA health system has recently turned to the antiviral drug remdesivir and convalescent plasma from people who have recovered from infection with the new coronavirus, the AP reported.
The VA’s website says 13,657 veterans have been infected with the new coronavirus, and 1,200 have died. Some veterans’ groups demanded the VA explain its use of hydroxychloroquine after data showed that the drug provided no benefit to veterans who received it. The death rate for veterans who received the drug plus usual care was 28 percent compared with 11 percent of those who received usual care alone, the AP reported.
Paternal Exposure to Valproate Not Linked to Offspring Neurodevelopmental Disorders 
Drug Retention in Spondyloarthritis Varies With Socioeconomic Status 
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer 
December 2024 to 2025 Saw Significant Increase in Leucovorin Dispensing 
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings 
Dexrazoxane Offers Lasting Doxorubicin Cardioprotective Effect in Childhood Cancer Survivors 
Many With Atypical Alzheimer Disease Do Not Qualify for Anti-Amyloid Therapy 
Study IDs Neurobiological Roots of Sensory Over-Responsivity 
